Clinical trials
Dermatomyositis clinical trials
Below are recruiting dermatomyositis clinical trials, each written for real people, not researchers. We’re tracking 39 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06685042RecruitingPhase 1/Phase 2
CAR T-cell therapy for severe autoimmune diseases
This study tests a new treatment called CAR T-cell therapy for people with severe autoimmune diseases that haven't gotten better with standard treatments. The goal is to see if it can help control the disease by reprogramming your immune cells.
Rome, LazioAges 18–65 - NCT07184450RecruitingPhase 1
CAR-T cell therapy for children with hard-to-treat rheumatic diseases
This trial tests a new treatment using your child's own immune cells, modified to target B cells and fight severe rheumatic diseases like juvenile dermatomyositis, arthritis, scleroderma, or Sjogren's syndrome. It's for children who haven't improved with standard treatments.
Hangzhou, ZhejiangAges 5 years+ - NCT07089121RecruitingPhase 1/Phase 2
Descartes-08 for young people with autoimmune diseases
This trial tests a new therapy called Descartes-08 for children, teens, and young adults with autoimmune conditions like lupus, myasthenia gravis, or dermatomyositis. It aims to see if it can help control moderate disease that hasn't responded well enough to other treatments.
Washington D.C., District of ColumbiaAges 12 years+ - NCT06723106Enrolling by invitationPhase 1
Long-term safety study of RAY121 for immune conditions
This study is for people who already took RAY121 in a previous trial and did well. It tests whether continuing the treatment is safe and effective over a longer period. The goal is to manage chronic immune conditions.
Camperdown, New South WalesAges 18–85 - NCT06698796RecruitingPhase 3
Study of dazukibart for ongoing idiopathic inflammatory myopathies
This trial studies the long-term effects of dazukibart in people who completed an earlier study for idiopathic inflammatory myopathies (a group of rare conditions causing muscle inflammation and weakness). It helps researchers understand how well the medicine works over a longer period.
Glendale, ArizonaAges 18 years+ - NCT06672822RecruitingPhase 2
STS injections for calcinosis in scleroderma
This trial tests if injecting a medication called STS directly into calcium deposits can relieve pain and symptoms. It may help patients with scleroderma or related conditions who have painful calcium lumps.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06599411Recruiting
Skin biomarkers for inflammatory disease treatment
This study looks for clues in your skin and blood that could predict how well you'll respond to treatments for conditions like eczema, psoriasis, or lupus. It aims to help doctors choose the best therapy for you.
ParisAges 18 years+ - NCT06371417RecruitingPhase 1
Testing RAY121 for several immune diseases (RAINBOW trial)
This trial tests a new medicine called RAY121 (an antibody) for people with certain autoimmune diseases. It aims to see if RAY121 is safe and how the body handles it. If you have one of these conditions and meet the basic health requirements, you might be able to join.
Orange, CaliforniaAges 18–85 - NCT06347718RecruitingPhase 1/Phase 2
Car-T cells for autoimmune disease
This study tests a type of immunotherapy called CAR-T cells for people with certain autoimmune diseases like lupus, scleroderma, or myositis. It aims to see if this treatment can help when standard medicines haven't worked well enough.
Erlangen, BavariaAges 18 years+ - NCT05979441Enrolling by invitationPhase 3
Long-term safety of efgartigimod injection for myositis
This study tests the long-term safety and effectiveness of a subcutaneous (under-the-skin) version of efgartigimod for adults with active idiopathic inflammatory myopathy. It is for people who have already completed an earlier study of this medicine.
Phoenix, ArizonaAges 18 years+ - NCT05895786RecruitingPhase 3
Study drug for active dermatomyositis or polymyositis
This Phase 3 trial tests how an investigational medicine (PF-06823859) works in adults with active dermatomyositis or polymyositis. It aims to improve disease control by targeting the immune system, but you must meet several safety and diagnosis requirements.
Glendale, ArizonaAges 18 years+ - NCT04402086Recruiting
Rheumatology patient and skin sample registry study at Yale
This study builds a health record and blood/skin sample collection for people with rheumatic autoimmune diseases who are getting care at Yale. It may help researchers understand these conditions and develop better tests or treatments over time.
New Haven, ConnecticutAges 18–99 - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune disease
This trial tests whether the immunotherapy drug nivolumab can safely treat advanced cancer in people who also have an autoimmune disease like rheumatoid arthritis, lupus, or multiple sclerosis. It aims to find out if the drug may help control cancer while managing their autoimmune condition.
Birmingham, AlabamaAges 18 years+ - NCT03582800RecruitingPhase 2
Sodium thiosulfate shots for abnormal calcium or bone spots
This pilot study tests a medicine called sodium thiosulfate (given as a skin shot) to treat abnormal calcium or bone formation in places they don’t belong. It’s meant for people whose condition is causing significant problems, and who are not planning surgery for the next year.
BordeauxAges 6 months+ - NCT00017914Recruiting
Understanding muscle inflammation: adult and juvenile myositis study
This research study helps doctors better understand myositis—a group of rare diseases that cause muscle inflammation and weakness. Researchers collect blood samples, medical history, and sometimes muscle biopsies to learn more about what causes these conditions and how to treat them better.
Atlanta, GeorgiaAges 2–100
Hear when a new Dermatomyositis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for dermatomyositis?
- Yes. Clin2 currently lists 39 recruiting dermatomyositis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a dermatomyositis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a dermatomyositis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.